Inhaled therapies for tuberculosis and the relevance of activation of lung macrophages by particulate drug-delivery systems

Therapeutic Delivery

Volumn 2, Issue 6, 2011, Pages 753-768

  Verma, Rahul Kumar ^a   Singh, Amit Kumar ^a   Mohan, Mradul ^a   Agrawal, Atul Kumar ^a   Misra, Amit ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOSALICYLIC ACID; BCG VACCINE; CAPREOMYCIN; CAPREOMYCIN OLEATE; CHEMOKINE; GAMMA INTERFERON; GROWTH FACTOR; INFLAMMASOME; ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID PLUS RIFABUTIN; ISONIAZID PLUS RIFAMPICIN; LIPOSOME; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NANOPARTICLE; NITRIC OXIDE SYNTHASE; P 824; POLYPEPTIDE ANTIBIOTIC AGENT; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; RECOMBINANT ANTIGEN 85; RIFAMPICIN; RV1733C ANTIGEN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

AERATION; ANTIGEN PRESENTATION; APOPTOSIS; AUTOPHAGY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRY POWDER; HUMAN; HYDROPHOBICITY; IMMUNE RESPONSE; INHALATION; LUNG ALVEOLUS MACROPHAGE; MACROPHAGE ACTIVATION; MYCOBACTERIUM TUBERCULOSIS; NEBULIZATION; NONHUMAN; PHAGOCYTOSIS; PHAGOSOME; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RESPIRATORY BURST; REVIEW; SIGNAL TRANSDUCTION; SURFACE PROPERTY; TH1 CELL; TH2 CELL; TUBERCULOSIS;

EID: 79960252887     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.11.34     Document Type: Review

References (149)

1. Muttil P, Kaur J, Kumar K, Yadav AB, Sharma R, Misra A. Inhalable microparticles containing large payload of antituberculosis drugs. Eur. J. Pharm. Sci. 32(2), 140-150 (2007) (Pubitemid 47285721)
2. Hirota K, Hasegawa T, Nakajima T et al. Delivery of rifampicin-PLGA microspheres into alveolar macrophages is promising for treatment of tuberculosis. J. Control. Release 142(3), 339-346 (2010)
3. Sharma R, Muttil P, Yadav AB et al. Uptake of inhalable microparticles affects defense responses of macrophages infected with Mycobacterium tuberculosis H37Ra. J. Antimicrob. Chemother. 59(3), 499-506 (2007) (Pubitemid 47073457)
4. Pandey R, Zahoor A, Sharma S, Khuller GK. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Tuberculosis 83(6), 373-378 (2003) (Pubitemid 37464042)
5. Chimote G, Banerjee R. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J. Biomed. Mater. Res. B Appl. Biomater. 94(1), 1-10 (2010)
6. Deol P, Khuller GK, Joshi K. Therapeutic efficacies of isoniazid and rifampin encapsulated in lung-specific stealth liposomes against Mycobacterium tuberculosis infection induced in mice. Antimicrob. Agents Chemother. 41(6), 1211-1214 (1997) (Pubitemid 27231415)
7. Suarez S, OHara P, Kazantseva M et al. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm. Res. 18(9), 1315-1319 (2001) (Pubitemid 32846326)
8. Garcia-Contreras L, Fiegel J, Telko MJ et al. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob. Agents Chemother. 51(8), 2830-2836 (2007) (Pubitemid 47206218)
9. Garcia-Contreras L, Sung JC, Muttil P et al. Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs. Antimicrob. Agents Chemother. 54(4), 1436-1442 (2010)
10. Verma RK, Kaur J, Kumar K, Yadav AB, Misra A. Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice. Antimicrob. Agents Chemother. 52(9), 3195-3201 (2008)
11. Suarez S, OHara P, Kazantseva M et al. Airway delivery of rifampicin microparticles for the treatment of tuberculosis. J. Antimicrob. Chemother. 48(3), 431-434 (2001) (Pubitemid 32898818)
12. Tabata Y, Ikada Y. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9(4), 356-362 (1988)
13. Ayhan H, Tuncel A, Bor N, Piskin E. Phagocytosis of monosize polystyrene-based microspheres having different size and surface properties. J. Biomater. Sci. Polym. Ed. 7(4), 329-342 (1995)
14. Prior S, Gander B, Blarer N et al. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres. Eur. J. Pharm. Sci. 15(2), 197-207 (2002) (Pubitemid 34155382)
15. Yadav AB, Muttil P, Singh AK et al. Microparticles induce variable levels of activation in macrophages infected with Mycobacterium tuberculosis. Tuberculosis (Edinb.) 90(3), 188-196 (2010)
16. Sharma R, Saxena D, Dwivedi AK, Misra A. Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis. Pharm. Res. 18(10), 1405-1410 (2001) (Pubitemid 32977245)
17. Yadav AB, Misra A. Enhancement of apoptosis of THP-1 cells infected with Mycobacterium tuberculosis by inhalable microparticles and relevance to bactericidal activity. Antimicrob. Agents Chemother. 51(10), 3740-3742 (2007) (Pubitemid 47519369)
18. Yadav AB, Sharma R, Muttil P et al. Inhalable microparticles containing isoniazid and rifabutin target macrophages and stimulate the phagocyte to achieve high efficacy. Indian J. Exp. Biol. 47(6), 469-474 (2009)
19. Holian A, Kelley K, Hamilton RF Jr. Mechanisms associated with human alveolar macrophage stimulation by particulates. Environ. Health Perspect. 102(Suppl. 10), 69-74 (1994)
20. Artursson P, Arro E, Edman P, Ericsson JL, Sjoholm I. Biodegradable microspheres. V: stimulation of macrophages with microparticles made of various polysaccharides. J. Pharm. Sci. 76(2), 127-133 (1987) (Pubitemid 17043678)
21. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 32(5), 593-604 (2010)
22. Cohn ZA. Activation of mononuclear phagocytes: fact, fancy, and future. J. Immunol. 121(3), 813-816 (1978) (Pubitemid 9012084)
23. Ernst JD. Macrophage receptors for Mycobacterium tuberculosis. Infect. Immun. 66(4), 1277-1281 (1998) (Pubitemid 128471479)
24. Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol. 3(1), 23-35 (2003) (Pubitemid 37328697)
25. Redente EF, Higgins DM, Dwyer-Nield LD, Orme IM, Gonzalez-Juarrero M, Malkinson AM. Differential polarization of alveolar macrophages and bone marrow-derived monocytes following chemically and pathogen-induced chronic lung inflammation. J. Leukoc. Biol. 88(1), 159-168 (2010)
26. Nathan C. Mechanisms and modulation of macrophage activation. Behring Inst Mitt (88), 200-207 (1991)
27. Meldrum DR, Cleveland JC Jr, Moore EE, Partrick DA, Banerjee A, Harken AH. Adaptive and maladaptive mechanisms of cellular priming. Ann. Surg. 226(5), 587-598 (1997) (Pubitemid 28049654)
28. Van Ginderachter JA, Movahedi K, Hassanzadeh Ghassabeh G et al. Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion. Immunobiology 211(6-8), 487-501 (2006)
29. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu. Rev. Biochem. 67, 227-264 (1998) (Pubitemid 28411130)
30. Ehrt S, Schnappinger D, Bekiranov S et al. Reprogramming of the macrophage transcriptome in response to interferon-g and Mycobacterium tuberculosis: signaling roles of nitric oxide synthase-2 and phagocyte oxidase. J. Exp. Med. 194(8), 1123-1140 (2001)
31. Mosser DM. The many faces of macrophage activation. J. Leukoc. Biol. 73(2), 209-212 (2003) (Pubitemid 36158295)
32. Day J, Friedman A, Schlesinger LS. Modeling the immune rheostat of macrophages in the lung in response to infection. Proc. Natl Acad. Sci. USA 106(27), 11246-11251 (2009)
33. Wang J, Wakeham J, Harkness R, Xing Z. Macrophages are a significant source of type 1 cytokines during mycobacterial infection. J. Clin. Invest. 103(7), 1023-1029 (1999) (Pubitemid 29169610)
34. Hansen K, Mossman BT. Generation of superoxide (O2-.) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res. 47(6), 1681-1686 (1987) (Pubitemid 17044503)
35. Nau GJ, Richmond JF, Schlesinger A, Jennings EG, Lander ES, Young RA. Human macrophage activation programs induced by bacterial pathogens. Proc. Natl Acad. Sci. USA 99(3), 1503-1508 (2002) (Pubitemid 34136522)
36. Scanga CA, Mohan VP, Tanaka K, Alland D, Flynn JL, Chan J. The inducible nitric oxide synthase locus confers protection against aerogenic challenge of both clinical and laboratory strains of Mycobacterium tuberculosis in mice. Infect. Immun. 69(12), 7711-7717 (2001) (Pubitemid 33086601)
37. Kwon OJ. The role of nitric oxide in the immune response of tuberculosis. J. Korean Med. Sci. 12(6), 481-487 (1997) (Pubitemid 127711382)
38. Stenger S, Hanson DA, Teitelbaum R et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282(5386), 121-125 (1998) (Pubitemid 28471143)
39. Bowdish DM, Davidson DJ, Hancock RE. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol. 306, 27-66 (2006) (Pubitemid 47400317)
40. Raveh D, Kruskal BA, Farland J, Ezekowitz RA. Th1 and Th2 cytokines cooperate to stimulate mannose-receptor-mediated phagocytosis. J. Leukoc. Biol. 64(1), 108-113 (1998) (Pubitemid 28304683)
41. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon g in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178(6), 2249-2254 (1993) (Pubitemid 23344886)
42. Chan J, Xing Y, Magliozzo RS, Bloom BR. Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages. J. Exp. Med. 175(4), 1111-1122 (1992)
43. Flynn JL, Goldstein MM, Triebold KJ, Koller B, Bloom BR. Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. Proc. Natl Acad. Sci. USA 89(24), 12013-12017 (1992) (Pubitemid 23004775)
44. Condos R, Rom WN, Schluger NW. Treatment of multidrug-resistant pulmonary tuberculosis with interferon-g via aerosol. Lancet 349(9064), 1513-1515 (1997) (Pubitemid 27216363)
45. Engele M, Stossel E, Castiglione K et al. Induction of TNF in human alveolar macrophages as a potential evasion mechanism of virulent Mycobacterium tuberculosis. J. Immunol. 168(3), 1328-1337 (2002) (Pubitemid 34094503)
46. Feng CG, Jankovic D, Kullberg M et al. Maintenance of pulmonary Th1 effector function in chronic tuberculosis requires persistent IL-12 production. J. Immunol. 174(7), 4185-4192 (2005) (Pubitemid 40395997)
47. Lazarevic V, Martinon F. Linking inflammasome activation and phagosome maturation. Cell Host Microbe 3(4), 199-200 (2008) (Pubitemid 351494721)
48. Deretic V, Delgado M, Vergne I et al. Autophagy in immunity against mycobacterium tuberculosis: a model system to dissect immunological roles of autophagy. Curr. Top. Microbiol. Immunol. 335, 169-188 (2009)
49. Kelly DM, ten Bokum AM, OLeary SM, OSullivan MP, Keane J. Bystander macrophage apoptosis after Mycobacterium tuberculosis H37Ra infection. Infect. Immun. 76(1), 351-360 (2008)
50. Lazarevic V, Martinon F. Linking inflammasome activation and phagosome maturation. Cell Host Microbe 3(4), 199-200 (2008) (Pubitemid 351494721)
51. Master SS, Rampini SK, Davis AS et al. Mycobacterium tuberculosis prevents inflammasome activation. Cell Host Microbe 3(4), 224-232 (2008) (Pubitemid 351494718)
52. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis survival in infected macrophages. Cell 119(6), 753-766 (2004) (Pubitemid 40017683)
53. Alonso S, Pethe K, Russell DG, Purdy GE. Lysosomal killing of Mycobacterium mediated by ubiquitin-derived peptides is enhanced by autophagy. Proc. Natl Acad. Sci. USA 104(14), 6031-6036 (2007) (Pubitemid 47175653)
54. Keane J, Remold HG, Kornfeld H. Virulent Mycobacterium tuberculosis strains evade apoptosis of infected alveolar macrophages. J. Immunol. 164(4), 2016-2020 (2000) (Pubitemid 30108758)
55. Holscher C, Arendse B, Schwegmann A, Myburgh E, Brombacher F. Impairment of alternative macrophage activation delays cutaneous leishmaniasis in nonhealing BALB/c mice. J. Immunol. 176(2), 1115-1121 (2006) (Pubitemid 43099713)
56. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J. Exp. Med. 176(1), 287-292 (1992)
57. Doyle AG, Herbein G, Montaner LJ et al. Interleukin-13 alters the activation state of murine macrophages in vitro: comparison with interleukin-4 and interferon-g. Eur. J. Immunol. 24(6), 1441-1445 (1994) (Pubitemid 24169531)
58. OShea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327(5969), 1098-1102 (2010)
59. Pesce J, Kaviratne M, Ramalingam TR et al. The IL-21 receptor augments Th2 effector function and alternative macrophage activation. J. Clin. Invest. 116(7), 2044-2055 (2006) (Pubitemid 44033328)
60. Kahnert A, Seiler P, Stein M et al. Alternative activation deprives macrophages of a coordinated defense program to Mycobacterium tuberculosis. Eur. J. Immunol. 36(3), 631-647 (2006)
61. Moreno C, Mehlert A, Lamb J. The inhibitory effects of mycobacterial lipoarabinomannan and polysaccharides upon polyclonal and monoclonal human T cell proliferation. Clin. Exp. Immunol. 74(2), 206-210 (1988)
62. Chan J, Fan XD, Hunter SW, Brennan PJ, Bloom BR. Lipoarabinomannan, a possible virulence factor involved in persistence of Mycobacterium tuberculosis within macrophages. Infect. Immun. 59(5), 1755-1761 (1991)
63. Surcel HM, Troye-Blomberg M, Paulie S et al. Th1/Th2 profiles in tuberculosis, based on the proliferation and cytokine response of blood lymphocytes to mycobacterial antigens. Immunology 81(2), 171-176 (1994) (Pubitemid 24223189)
64. Friedland JS, Hartley JC, Hartley CG, Shattock RJ, Griffin GE. Inhibition of ex vivo proinflammatory cytokine secretion in fatal Mycobacterium tuberculosis infection. Clin. Exp. Immunol. 100(2), 233-238 (1995)
65. Pabst MJ, Gross JM, Brozna JP, Goren MB. Inhibition of macrophage priming by sulfatide from Mycobacterium tuberculosis. J. Immunol. 140(2), 634-640 (1988)
66. Launois P, Blum L, Dieye A, Millan J, Sarthou JL, Bach MA. Phenolic glycolipid-1 from M. leprae inhibits oxygen free radical production by human mononuclear cells. Res. Immunol. 140(9), 847-855 (1989) (Pubitemid 20040947)
67. Lee WL, Gold B, Darby C et al. Mycobacterium tuberculosis expresses methionine sulphoxide reductases A and B that protect from killing by nitrite and hypochlorite. Mol. Microbiol. 71(3), 583-593 (2009)
68. Ehrt S, Shiloh MU, Ruan J et al. A novel antioxidant gene from Mycobacterium tuberculosis. J. Exp. Med. 186(11), 1885-1896 (1997) (Pubitemid 27524598)
69. Ruan J, St John G, Ehrt S, Riley L, Nathan C. noxR3, a novel gene from Mycobacterium tuberculosis, protects Salmonella typhimurium from nitrosative and oxidative stress. Infect. Immun. 67(7), 3276-3283 (1999) (Pubitemid 29291491)
70. Hillas PJ, del Alba FS, Oyarzabal J, Wilks A, Ortiz De Montellano PR. The AhpC and AhpD antioxidant defense system of Mycobacterium tuberculosis. J. Biol. Chem. 275(25), 18801-18809 (2000) (Pubitemid 30422841)
71. Koo IC, Wang C, Raghavan S, Morisaki JH, Cox JS, Brown EJ. ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection. Cell Microbiol. 10(9), 1866-1878 (2008)
72. Mishra BB, Moura-Alves P, Sonawane A et al. Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the NLRP3/ASC inflammasome. Cell Microbiol. 12(8), 1046-1063 (2010)
73. Carlsson F, Kim J, Dumitru C et al. Host-detrimental role of Esx-1-mediated inflammasome activation in mycobacterial infection. PLoS Pathog. 6(5), e1000895 (2010)
74. Deretic V, Singh S, Master S et al. Mycobacterium tuberculosis inhibition of phagolysosome biogenesis and autophagy as a host defense mechanism. Cell Microbiol. 8(5), 719-727 (2006)
75. Riendeau CJ, Kornfeld H. THP-1 cell apoptosis in response to mycobacterial infection. Infect. Immun. 71(1), 254-259 (2003) (Pubitemid 36026027)
76. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-a. J. Immunol. 161(5), 2636-2641 (1998) (Pubitemid 28397084)
77. Placido R, Mancino G, Amendola A et al. Apoptosis of human monocytes/macrophages in Mycobacterium tuberculosis infection. J. Pathol. 181(1), 31-38 (1997) (Pubitemid 27099771)
78. Geiser M, Cruz-Orive LM, Im Hof V, Gehr P. Assessment of particle retention and clearance in the intrapulmonary conducting airways of hamster lungs with the fractionator. J. Microsc. 160(Pt 1), 75-88 (1990) (Pubitemid 20347010)
79. Geiser M, Baumann M, Cruz-Orive LM, Im Hof V, Waber U, Gehr P. The effect of particle inhalation on macrophage number and phagocytic activity in the intrapulmonary conducting airways of hamsters. Am. J. Respir. Cell Mol. Biol. 10(6), 594-603 (1994)
80. Dorger M, Krombach F. Interaction of alveolar macrophages with inhaled mineral particulates. J. Aerosol. Med. 13(4), 369-380 (2000) (Pubitemid 32105622)
81. Tabata Y, Inoue Y, Ikada Y. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14(17-18), 1677-1685 (1996) (Pubitemid 27041922)
82. Nagao G, Ishii K, Hirota K, Makino K, Terada H. Role of lipid rafts in phagocytic uptake of polystyrene latex microspheres by macrophages. Anticancer Res. 30(8), 3167-3176 (2010)
83. Thakur SA, Hamilton R Jr, Pikkarainen T, Holian A. Differential binding of inorganic particles to MARCO. Toxicol. Sci. 107(1), 238-246 (2009)
84. Thakur SA, Hamilton RF Jr, Holian A. Role of scavenger receptor a family in lung inflammation from exposure to environmental particles. J. Immunotoxicol. 5(2), 151-157 (2008) (Pubitemid 351882420)
85. Haberzettl P, Schins RP, Hohr D, Wilhelmi V, Borm PJ, Albrecht C. Impact of the FcgII-receptor on quartz uptake and inflammatory response by alveolar macrophages. Am. J. Physiol. Lung Cell Mol. Physiol. 294(6), L1137-L1148 (2008)
86. Ayhan H, Piskin E. Interaction of activated leukocytes with polymeric microspheres. Int. J. Artif. Organs 20(12), 704-707 (1997) (Pubitemid 28109137)
87. Stringer B, Imrich A, Kobzik L. Lung epithelial cell (A549) interaction with unopsonized environmental particulates: quantitation of particle-specific binding and IL-8 production. Exp. Lung Res. 22(5), 495-508 (1996) (Pubitemid 26314109)
88. Stringer B, Kobzik L. Alveolar macrophage uptake of the environmental particulate titanium dioxide: role of surfactant components. Am. J. Respir. Cell Mol. Biol. 14(2), 155-160 (1996) (Pubitemid 126441388)
89. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, Langer R. Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2-dipalmitoylphosphatidylcholine. J. Control. Release 51(2-3), 143-152 (1998) (Pubitemid 28252865)
90. Lay JC, Alexis NE, Zeman KL, Peden DB, Bennett WD. In vivo uptake of inhaled particles by airway phagocytes is enhanced in patients with mild asthma compared with normal volunteers. Thorax 64(4), 313-320 (2009)
91. Saldiva PH, Clarke RW, Coull BA et al. Lung inflammation induced by concentrated ambient air particles is related to particle composition. Am. J. Respir. Crit. Care Med. 165(12), 1610-1617 (2002) (Pubitemid 34693940)
92. Sharma R, Yadav AB, Muttil P, Kajal H, Misra A. Inhalable microparticles modify cytokine secretion by lung macrophages of infected mice. Tuberculosis (Edinb) 91(1), 107-110 (2010)
93. Cantin A, Dubois F, Begin R. Lung exposure to mineral dusts enhances the capacity of lung inflammatory cells to release superoxide. J. Leukoc. Biol. 43(4), 299-303 (1988)
94. Dubois CM, Bissonnette E, Rola-Pleszczynski M. Asbestos fibers and silica particles stimulate rat alveolar macrophages to release tumor necrosis factor. Autoregulatory role of leukotriene B4. Am. Rev. Respir. Dis. 139(5), 1257-1264 (1989) (Pubitemid 19139854)
95. Lemaire I, Ouellet S. Distinctive profile of alveolar macrophage-derived cytokine release induced by fibrogenic and nonfibrogenic mineral dusts. J. Toxicol. Environ. Health 47(5), 465-478 (1996)
96. Lemaire I, Ouellet S. Role of transforming growth factor-b(1) in down-regulating TNF production by alveolar macrophages during asbestos-induced pulmonary fibrosis. Mediators Inflamm. 5(1), 37-42 (1996)
97. Driscoll KE, Higgins JM, Leytart MJ, Crosby LL. Differential effects of mineral dusts on the in vitro activation of alveolar macrophage eicosanoid and cytokine release. Toxicol. In vitro 4(4-5), 284-288 (1990) (Pubitemid 20364902)
98. Driscoll KE, Howard BW, Carter JM et al. α-quartz-induced chemokine expression by rat lung epithelial cells: effects of in vivo and in vitro particle exposure. Am J. Pathol. 149(5), 1627-1637 (1996) (Pubitemid 26363969)
99. Donaldson K, Slight J, Hannant D, Bolton RE. Increased release of hydrogen peroxide and superoxide anion from asbestos-primed macrophages. Effect of hydrogen peroxide on the functional activity of a1-protease inhibitor. Inflammation 9(2), 139-147 (1985) (Pubitemid 15036634)
100. Choe N, Tanaka S, Xia W, Hemenway DR, Roggli VL, Kagan E. Pleural macrophage recruitment and activation in asbestos-induced pleural injury. Environ. Health Perspect. 105(Suppl. 5), 1257-1260 (1997)
101. Sharp FA, Ruane D, Claass B et al. Uptake of particulate vaccine adjuvants by dendritic cells activates the NALP3 inflammasome. Proc. Natl Acad. Sci. USA 106(3), 870-875 (2009)
102. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J. Immunol. 174(8), 5016-5023 (2005) (Pubitemid 40514462)
103. Chen CJ, Shi Y, Hearn A et al. MyD88- dependent IL-1 receptor signaling is essential for gouty inflammation stimulated by monosodium urate crystals. J. Clin. Invest. 116(8), 2262-2271 (2006) (Pubitemid 44162336)
104. Popa-Nita O, Marois L, Pare G, Naccache PH. Crystal-induced neutrophil activation: X. Proinflammatory role of the tyrosine kinase Tec. Arthritis Rheum. 58(6), 1866-1876 (2008) (Pubitemid 351847542)
105. Jaramillo M, Godbout M, Naccache PH, Olivier M. Signaling events involved in macrophage chemokine expression in response to monosodium urate crystals. J. Biol. Chem. 279(50), 52797-52805 (2004) (Pubitemid 39656656)
106. Drumm K, Oettinger R, Smolarski R, Bay M, Kienast K. In vitro study of human alveolar macrophages inflammatory mediator transcriptions and releases induced by soot FR 101, Printex 90, titandioxide and Chrysotile B. Eur. J. Med. Res. 3(9), 432-438 (1998)
107. Refsnes M, Hetland RB, Ovrevik J, Sundfor I, Schwarze PE, Lag M. Different particle determinants induce apoptosis and cytokine release in primary alveolar macrophage cultures. Part. Fibre Toxicol. 3, 10 (2006)
108. Kang Y, Wu J, Yin G et al. Preparation, characterization and in vitro cytotoxicity of indomethacin-loaded PLLA/PLGA microparticles using supercritical CO2 technique. Eur. J. Pharm. Biopharm. 70(1), 85-97 (2008)
109. Evans SM, Ashwood P, Warley A, Berisha F, Thompson RP, Powell JJ. The role of dietary microparticles and calcium in apoptosis and interleukin-1β release of intestinal macrophages. Gastroenterology 123(5), 1543-1553 (2002) (Pubitemid 35231654)
110. Attwood EM, Weich DJ, Oosthuizen JM. Influence of carbon particles on superoxide and hydrogen peroxide radical release during the killing of Mycobacterium bovis by alveolar macrophages. Tuber. Lung Dis. 77(5), 462-467 (1996) (Pubitemid 26390476)
111. Robinson JM, Badwey JA. Production of active oxygen species by phagocytic leukocytes. Immunol. Ser. 60, 159-178 (1994)
112. Hirota K, Tomoda K, Inagawa H et al. Stimulation of phagocytic activity of alveolar macrophages toward artificial microspheres by infection with mycobacteria. Pharm. Res. 25(6), 1420-1430 (2008)
113. Biggs DL, Lengsfeld CS, Hybertson BM, Ng KY, Manning MC, Randolph TW. In vitro and in vivo evaluation of the effects of PLA microparticle crystallinity on cellular response. J. Control. Release 92(1-2), 147-161 (2003) (Pubitemid 37130129)
114. Garcia-Contreras L, Sethuraman V, Kazantseva M, Godfrey V, Hickey AJ. Evaluation of dosing regimen of respirable rifampicin biodegradable microspheres in the treatment of tuberculosis in the guinea pig. J. Antimicrob. Chemother. 58(5), 980-986 (2006)
115. Yoshida A, Matumoto M, Hshizume H et al. Selective delivery of rifampicin incorporated into poly(dl-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin. Microbes Infect. 8(9-10), 2484-2491 (2006) (Pubitemid 44499050)
116. Tsapis N, Bennett D, ODriscoll K et al. Direct lung delivery of para-aminosalicylic acid by aerosol particles. Tuberculosis (Edinb.) 83(6), 379-385 (2003) (Pubitemid 37464043)
117. Wang C, Hickey AJ. Isoxyl aerosols for tuberculosis treatment: preparation and characterization of particles. AAPS PharmSciTech 11(2), 538-549 (2010)
118. Lu D, Garcia-Contreras L, Muttil P et al. Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity. AAPS J. 12(3), 338-347 (2010)
119. Giovagnoli S, Blasi P, Schoubben A, Rossi C, Ricci M. Preparation of large porous biodegradable microspheres by using a simple double-emulsion method for capreomycin sulfate pulmonary delivery. Int. J. Pharm. 333(1-2), 103-111 (2007) (Pubitemid 46283276)
120. Schoubben A, Blasi P, Giovagnoli S, Ricci M, Rossi C. Simple and scalable method for peptide inhalable powder production. Eur. J. Pharm. Sci. 39(1-3), 53-58 (2010)
121. Sharma A, Pandey R, Sharma S, Khuller GK. Chemotherapeutic efficacy of poly (dl-lactide-co-glycolide) nanoparticle encapsulated antitubercular drugs at sub-therapeutic dose against experimental tuberculosis. Int. J. Antimicrob. Agents 24(6), 599-604 (2004) (Pubitemid 39536116)
122. Bivas-Benita M, Lin MY, Bal SM et al. Pulmonary delivery of DNA encoding Mycobacterium tuberculosis latency antigen Rv1733c associated to PLGA-PEI nanoparticles enhances T cell responses in a DNA prime/protein boost vaccination regimen in mice. Vaccine 27(30), 4010-4017 (2009)
123. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int. J. Pharm. 269(1), 37-49 (2004) (Pubitemid 38035210)
124. Ricci M, Giovagnoli S, Blasi P, Schoubben A, Perioli L, Rossi C. Development of liposomal capreomycin sulfate formulations: effects of formulation variables on peptide encapsulation. Int. J. Pharm. 311(1-2), 172-181 (2006)
125. Fiegel J, Garcia-Contreras L, Thomas M et al. Preparation and in vivo evaluation of a dry powder for inhalation of capreomycin. Pharm. Res. 25(4), 805-811 (2008) (Pubitemid 351661830)
126. Morello M, Krone CL, Dickerson S et al. Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis (Edinb.) 89(5), 371-377 (2009)
127. Tyagi S, Nuermberger E, Yoshimatsu T et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother. 49(6), 2289-2293 (2005) (Pubitemid 40734456)
128. Sung JC, Garcia-Contreras L, Verberkmoes JL et al. Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother. 53(4), 1338-1343 (2009)
129. Hasan Z, Zaidi I, Jamil B, Khan MA, Kanji A, Hussain R. Elevated ex vivo monocyte chemotactic protein-1 (CCL2) in pulmonary as compared with extra-pulmonary tuberculosis. BMC Immunol. 6, 14 (2005)
130. Saukkonen JJ, Bazydlo B, Thomas M, Strieter RM, Keane J, Kornfeld H. β-chemokines are induced by Mycobacterium tuberculosis and inhibit its growth. Infect. Immun. 70(4), 1684-1693 (2002) (Pubitemid 34242168)
131. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 a with a Th2-associated expression pattern. J. Immunol. 160(3), 1411-1418 (1998) (Pubitemid 28093442)
132. Roursgaard M, Poulsen SS, Poulsen LK et al. Time-response relationship of nano and micro particle induced lung inflammation. Quartz as reference compound. Hum. Exp. Toxicol. 29(11), 915-933 (2010)
133. Wilson DW, Aung HH, Lame MW et al. Exposure of mice to concentrated ambient particulate matter results in platelet and systemic cytokine activation. Inhal. Toxicol. 22(4), 267-276 (2010)
134. Bonato VL, Medeiros AI, Lima VM, Dias AR, Faccioliti LH, Silva CL. Downmodulation of CD18 and CD86 on macrophages and VLA-4 on lymphocytes in experimental tuberculosis. Scand. J. Immunol. 54(6), 564-573 (2001) (Pubitemid 34131765)
135. DesJardin LE, Kaufman TM, Potts B, Kutzbach B, Yi H, Schlesinger LS. Mycobacterium tuberculosis-infected human macrophages exhibit enhanced cellular adhesion with increased expression of LFA-1 and ICAM-1 and reduced expression and/or function of complement receptors, FcgRII and the mannose receptor. Microbiology 148(Pt 10), 3161-3171 (2002) (Pubitemid 35243716)
136. Hibbs JB Jr. Infection and nitric oxide. J. Infect. Dis. 185(Suppl. 1), S9-S17 (2002) (Pubitemid 34142824)
137. Dostert C, Petrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320(5876), 674-677 (2008) (Pubitemid 351928351)
138. Hirota K, Hasegawa T, Hinata H et al. Optimum conditions for efficient phagocytosis of rifampicin-loaded PLGA microspheres by alveolar macrophages. J. Control. Release 119(1), 69-76 (2007) (Pubitemid 46561547)
139. Shanbhag AS, Jacobs JJ, Black J, Galante JO, Glant TT. Macrophage/particle interactions: effect of size, composition and surface area. J. Biomed. Mater. Res. 28(1), 81-90 (1994) (Pubitemid 24006480)
140. St Pierre C, Zhu J, Hayward J, Kurt-Jones E. Size and shape matter: role of surface curvature in inflammasome activation by synthetic microparticles J. Immunol. 2010(184), 136-139 (2010)
141. Roser M, Fischer D, Kissel T. Surface-modified biodegradable albumin nano- and microspheres. II: effect of surface charges on in vitro phagocytosis and biodistribution in rats. Eur. J. Pharm. Biopharm. 46(3), 255-263 (1998) (Pubitemid 29057671)
142. Tabata Y, Ikada Y. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres. J. Pharm. Pharmacol. 39(9), 698-704 (1987) (Pubitemid 18015453)
143. Bianco C, Griffin FM Jr, Silverstein SC. Studies of the macrophage complement receptor. Alteration of receptor function upon macrophage activation. J. Exp. Med. 141(6), 1278-1290 (1975)
144. Wright SD. Cellular strategies in receptor-mediated phagocytosis. Rev. Infect. Dis. 7(3), 395-397 (1985)
145. Artursson P, Johansson D, Sjoholm I. Receptor-mediated uptake of starch and mannan microparticles by macrophages: relative contribution of receptors for complement, immunoglobulins and carbohydrates. Biomaterials 9(3), 241-246 (1988)
146. Moller W, Hofer T, Ziesenis A, Karg E, Heyder J. Ultrafine particles cause cytoskeletal dysfunctions in macrophages. Toxicol. Appl. Pharmacol. 182(3), 197-207 (2002)
147. Rieger AM, Hall BE, Barreda DR. Macrophage activation differentially modulates particle binding, phagocytosis and downstream antimicrobial mechanisms. Dev. Comp. Immunol. 34(11), 1144-1159 (2010)
148. Terada H. US2010/0178354A1 (2010)
149. Council of Scientific and Industrial Research; Lupin limited. US20070154408 (2005)